Cargando…
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Immune checkpoint inhibitors (e.g., anti-PD-1 and anti-PD-L1 antibodies) have demonstrated remarkable efficacy against hypermutated cancers such as melanomas and lung carcinomas. One explanation for this effect is that hypermutated lesions harbor more tumor-specific neoantigens that stimulate recrui...
Autores principales: | Strickland, Kyle C., Howitt, Brooke E., Shukla, Sachet A., Rodig, Scott, Ritterhouse, Lauren L., Liu, Joyce F., Garber, Judy E., Chowdhury, Dipanjan, Wu, Catherine J., D'Andrea, Alan D., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924663/ https://www.ncbi.nlm.nih.gov/pubmed/26871470 http://dx.doi.org/10.18632/oncotarget.7277 |
Ejemplares similares
-
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
por: Shukla, Sachet A., et al.
Publicado: (2016) -
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022) -
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020) -
PD-L1 Expression Affects Neoantigen Presentation
por: Okada, Masahiro, et al.
Publicado: (2020) -
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020)